Keyword: Harvoni

AbbVie inked a deal with the Medicines Patent Pool to boost access to hep C drug Mavyret in nearly 100 low- and middle-income countries and territories.

Express Scripts is rolling out a new formulary to assist drugmakers with lowering list prices.

Merck lost out when a judge nixed $200 million in patent damages, citing misconduct and fabricated testimony. Now it wants the Supreme Court to intervene.

Gilead and Express Scripts have clashed in hepatitis C before, but now that Gilead plans authorized generics of its own drugs, Express Scripts is on board.

Gilead's hepatitis C sales have eroded big-time, and the company is taking an unusual new tack that might deliver its drugs to new patients.

Gilead's promotion of Andrew Dickinson, and a fresh licensing deal, could signal that Gilead's looking outside its own walls for growth opportunities.

Gilead may have some exciting prospects ahead, but for now, its cash-cow hepatitis C business is a big drag. The good news? It's a 'trough year.'

Regeneron and Sanofi have an exclusive PCSK9 deal with Express Scripts, but one analyst believes it's a negative for the companies.

A Merck attorney who provided false testimony tainted the company's case, an appeals court ruled, and cost the company $200 million.